HER2 Alterations in Non-Small Cell Lung Cancer : Episode 2
Approaches to Biomarker Testing in NSCLC
Timothy Craig Allen, MD, JD, FCAP, explains how he approaches biomarker testing in NSCLC and what testing he would have ordered in the presented scenario.
EP: 1.Biomarker Testing in NSCLC: Clinical Scenario
Now Viewing
EP: 2.Approaches to Biomarker Testing in NSCLC
EP: 3.Liquid vs Solid Tumor Biopsies in NSCLC
EP: 4.HER2 Alterations in NSCLC: Clinical Scenario
EP: 5.The Role of HER2 Alterations in NSCLC
EP: 6.Testing Patients with NSCLC for HER2 Mutations
EP: 7.Current Treatment Options in NSCLC
EP: 8.Clinical Scenario: A 72-Year-Old Man with HER2-Amplified NSCLC
EP: 9.HER2-Targeted Therapies in NSCLC
EP: 10.Major Adverse Events of Anti-HER2 Therapies
EP: 11.Unmet Needs in NSCLC Therapy
EP: 12.Challenges and Unmet Needs in HER2-Mutated or Amplified NSCLC
EP: 13.Novel HER2-Targeted Therapies for NSCLC
Related Videos
Related Content
